BELITE BIO INC - ADR
BLTENASDAQTrading Snapshot
- Day Range
- $164.63 – $168.05
- 52-Week Range
- $70.17 – $200.00
- Volume
- $2.13B
- Avg Volume
- $2.40B
- Shares Outstanding
- 40.1M
- Next Earnings
- Dec 3, 2026
Fundamentals Snapshot
- Annual Revenue
- $576M
- Last Q Revenue
- $132M
- P/E Ratio
- -60.1
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.55
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +6.6%
Why Investors Own BLTE
- ✓High-growth profile — revenue up +46.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
BELITE BIO INC - ADR
BLTE
StockOtter · stockotter.spaceAbout BELITE BIO INC - ADR
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
SAN DIEGO, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative reti
Belite Bio, Inc. Sponsored ADR $BLTE Shares Sold by Squarepoint Ops LLC
Squarepoint Ops LLC reduced its position in shares of Belite Bio, Inc. Sponsored ADR (NASDAQ: BLTE) by 48.3% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
Belite Bio, Inc. Sponsored ADR (BLTE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, BLTE's 50-day simple moving average broke out above its 200-day mo
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1
SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative re
Why Is Belite Bio Stock Soaring Friday?
Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant.